← board
AGNPF
distress 6/10 · elevated risk$0.290%today-54% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.2 yrs
Shares 1y
—
Price & events
-25.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+4.9%
1W
+10.6%
1M
-20.4%
3M
-25.8%
6M
-18.5%
1Y
-58.1%
2Y
-97.9%
5Y
-99.3%
All
Overview
- Volume
- 0
- 52 Week Range
- $0.23 – $0.64
- Float Shares
- 4.94M
- % Held by Insiders
- 4.36%
- % Held by Institutions
- 17.64%
- Beta
- 0.93
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.